These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35763095)

  • 1. Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status.
    Park YW; Kim S; Park CJ; Ahn SS; Han K; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2022 Dec; 32(12):8089-8098. PubMed ID: 35763095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
    Park CJ; Han K; Kim H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6464-6474. PubMed ID: 32740813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal MRI-based radiomic nomogram for predicting telomerase reverse transcriptase promoter mutation in IDH-wildtype histological lower-grade gliomas.
    Huo X; Wang Y; Ma S; Zhu S; Wang K; Ji Q; Chen F; Wang L; Wu Z; Li W
    Medicine (Baltimore); 2023 Dec; 102(51):e36581. PubMed ID: 38134061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study.
    Alimohamadi M; Larijani A; Pour-Rashidi A; Farzin M; Ebrahimi H; Rahmani M; Hendi K; Yarandi KK; Aghajanian S; Shirani M
    World Neurosurg; 2024 Jan; 181():e628-e639. PubMed ID: 37914076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion- and Perfusion-Weighted MRI Radiomics for Survival Prediction in Patients with Lower-Grade Gliomas.
    Park CJ; Kim S; Han K; Ahn SS; Kim D; Park YW; Chang JH; Kim SH; Lee SK
    Yonsei Med J; 2024 May; 65(5):283-292. PubMed ID: 38653567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase reverse transcriptase promoter mutation and histologic grade in IDH wild-type histological lower-grade gliomas: The value of perfusion-weighted image, diffusion-weighted image, and
    Ikeda S; Sakata A; Fushimi Y; Okuchi S; Arakawa Y; Makino Y; Mineharu Y; Nakajima S; Hinoda T; Yoshida K; Miyamoto S; Nakamoto Y
    Eur J Radiol; 2023 Feb; 159():110658. PubMed ID: 36571926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas.
    Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B
    Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
    Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Jain R; Lee SK
    Eur Radiol; 2020 Jul; 30(7):3834-3842. PubMed ID: 32162004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas.
    Jiang C; Kong Z; Zhang Y; Liu S; Liu Z; Chen W; Liu P; Liu D; Wang Y; Lyu Y; Zhao D; Wang Y; You H; Feng F; Ma W
    Neuroradiology; 2020 Jul; 62(7):803-813. PubMed ID: 32239241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR image phenotypes may add prognostic value to clinical features in IDH wild-type lower-grade gliomas.
    Park CJ; Han K; Shin H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK
    Eur Radiol; 2020 Jun; 30(6):3035-3045. PubMed ID: 32060714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI Features May Predict Molecular Features of Glioblastoma in
    Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
    AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners.
    Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
    Berzero G; Di Stefano AL; Ronchi S; Bielle F; Villa C; Guillerm E; Capelle L; Mathon B; Laurenge A; Giry M; Schmitt Y; Marie Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M
    Neuro Oncol; 2021 Jun; 23(6):955-966. PubMed ID: 33173941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status.
    Park CJ; Choi YS; Park YW; Ahn SS; Kang SG; Chang JH; Kim SH; Lee SK
    Neuroradiology; 2020 Mar; 62(3):319-326. PubMed ID: 31820065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [
    Li Z; Kaiser L; Holzgreve A; Ruf VC; Suchorska B; Wenter V; Quach S; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4415-4425. PubMed ID: 34490493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas.
    Pei D; Guan F; Hong X; Liu Z; Wang W; Qiu Y; Duan W; Wang M; Sun C; Wang W; Wang X; Guo Y; Wang Z; Liu Z; Xing A; Guo Z; Luo L; Liu X; Cheng J; Zhang B; Zhang Z; Yan J
    Eur Radiol; 2023 May; 33(5):3455-3466. PubMed ID: 36853347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.